2026 HRT Label Changes Explained: What the FDA Removed, What It Kept, and What It Means for You

2026 HRT label changes explained: what actually changed?

A few definitions, so nothing here is fuzzy:

• HRT (hormone replacement therapy), also called menopausal hormone therapy, replaces the estrogen — and sometimes progesterone — your body makes less of around menopause.
• A boxed warning(you may know it as a “black box warning”) is the FDA's most serious label warning. It sits in a black-bordered box at the top of the prescribing information. It's the loudest thing on the label.
• Probable dementiais the exact phrase the FDA used — not “dementia” in general. That distinction matters, and you'll see why below.

This happened in two steps, months apart — which is why it may have felt like the news broke twice. On November 10, 2025, the FDA and the Department of Health and Human Services announced they would remove the warnings. Then on February 12, 2026, the FDA actually approved the first updated labels.

The FDA's reasoning, in plain terms: the old warning treated every woman, every age, and every product the same. Newer evidence says risk depends a lot on when you start and what you take. The agency now points to research showing women who start HRT within 10 years of menopause — generally before age 60 — tend to have lower overall death rates and fewer fractures (FDA press release, Feb 12, 2026).

While it was at it, the FDA also approved two new options: the first generic version of Premarin (a long-used conjugated-estrogen pill) in over 30 years, expected to improve affordability and access, and a non-hormonaltreatment for hot flashes for women who can't or won't use hormones (FDA/HHS, Nov 10, 2025). Most coverage missed this — but it widens your choices.

For the broader 2026 guidance picture, see our New HRT Guidelines 2026 roundup.

“Removed from the warning” doesn't mean “the risk is gone” — here's what we found in the actual labels

This is where we earn your trust, so we'll be blunt: a lot of headlines said “FDA deems HRT safe,” and a lot of clinic websites are repeating it. That's not what the labels say. We opened them.

Take Divigel (an estradiol skin gel) and Enjuvia (an oral estrogen) — both updated February 2026. Both still warn, in plain text, that estrogen-only therapy raises the risk of blood clots and stroke. Both still discuss breast cancer and recommend mammograms. And the list of conditions where you simply should not take them — the contraindications — was not softened. On both labels, that list still includes a current or past breast cancer, a history of blood clots, stroke, or heart attack, liver disease, and certain clotting disorders.

So read this carefully, because it's the whole point: the FDA changed how loudly these risks are stated, not whether they exist.Heart, clot, and breast-cancer information didn't vanish. It got moved out of the scariest box — because the FDA decided that one box was painting one extreme picture for every woman, when the real picture depends on your age, timing, and health. The labels even added something useful: a note that timing matters, and that these products should be considered for women under 60 or within 10 years of menopause.

Which HRT products got updated labels first — and what changed in each one?

This is the table no other consumer page has, because it takes opening six separate FDA labels to build it. Here is exactly what we found (all labels revised February 2026):

Sources: FDA updated-labels list and each product's FDA label, revised Feb 2026 — all linked in sources.

What this means in plain language:

• If your product is Divigel, Cenestin, or Enjuvia (estrogen by itself): the uterine-cancer warning stayed in the box. The heart, clot, and breast-cancer information is still in the label — just lower down.
• If your product is Bijuva (estrogen and progesterone in one capsule): the FDA removed the entire box, including uterine cancer — because the progesterone in it already addresses the uterine-lining risk. Heart and breast-cancer information still lives in the warnings section.
• If your product is Estring(a low-dose vaginal ring): its updated leaflet doesn't show a boxed warning at all. Very little of the estrogen gets into your bloodstream, which is why medical groups most strongly supported this change.
• If your product is Prometrium (progesterone): this is the hormone often added to estrogen to protect the uterus. More on that next.

The takeaway: don't assume the same change applies to your exact product. That's why we tracked all six separately — and why you should find your product by name on your label.

What warning stayed — and why does uterine cancer matter?

The word endometrialjust means the lining of the uterus. The simple version: estrogen tells that lining to grow. With no progesterone to balance it, the lining can build up and, over years, turn cancerous. That's why this one warning was deliberately kept on estrogen-only products (FDA/HHS, Nov 10, 2025).

So the rule of thumb that survived 2026 is this: if you have a uterus and take full-body (systemic) estrogen, your plan almost always needs to include an endometrial-protection step — usually a progestogen — not estrogen by itself. This is not a do-it-yourself decision. But now you know the why, and you know the number.

If you've had a hysterectomy (no uterus), this warning generally doesn't apply to you — which is exactly why “do you still have your uterus?” is one of the first questions in any HRT conversation.

What HRT warnings still remain after the 2026 label change?

Here's what's still in the updated labels, verified across the products we checked:

• Heart, clot, and stroke risk — still written into the Warnings and Precautions section of the systemic products (Divigel, Cenestin, Enjuvia, Bijuva).
• Breast cancer — still discussed, with a recommendation for breast exams and mammograms, and still listed as a condition where these products should not be used.
• The full contraindication list — unchanged: current or past breast cancer, undiagnosed vaginal bleeding, a history of blood clots, stroke or heart attack, liver disease, and certain clotting disorders.
• Gallbladder disease risk — still noted.
• The Women's Health Initiative studies — still described, just moved into the Clinical Studies section instead of the warning box.

Is vaginal estrogen different from systemic HRT after the label change?

The numbers tell the story. The Estring label shows that only about 8%of the estrogen it releases is absorbed into the body, and blood levels stay close to where they'd be without it (Estring FDA label, Feb 2026). That low, local exposure is why major medical groups were most comfortable with this part of the change.

The practical lesson: don't lump a vaginal ring and a full-body pill into the same risk conversation. They're different tools for different problems. If your main issue is vaginal dryness, painful sex, or urinary symptoms, local vaginal estrogen may be a different — and often lower-exposure — conversation than systemic HRT.

Does this mean HRT is safe now?

We'll say the quiet part out loud: the 2026 change is real and important, but it is nota green light for everyone. As we showed above, the heart, clot, and breast-cancer information is still right there in the labels. The honest framing is that HRT moved from “scary by default” to “a personal decision, based on your situation.”

A few things the change does not prove:

• It does not prove HRT prevents heart disease or dementia. The labels removed those warnings; they didn't add a promise.
• It does not mean every estrogen product carries the same risk. A vaginal ring and a full-body pill aren't the same conversation.
• It does not apply to compounded hormones.

The takeaway isn't “HRT is safe” or “HRT is dangerous.” It's: the right answer depends on you — your age, how long since your last period, whether you have a uterus, which product and route, and your personal and family history.

Why did the FDA change the warnings in the first place?

For 20 years, the WHI research shaped how millions of women felt about HRT. Higher rates of some risks in those trials triggered the 2003 boxed warning, and HRT use dropped sharply afterward. Here's the timeline the FDA points to:

Sources: FDA labeling-change request and press releases, 2025–2026.

The FDA's critique today is mostly about who was studied. The average participant was around 63 years old — well past the usual age of menopause — and the breast-cancer signal the agency now describes as a statistically non-significant increase. In plain terms: the studies largely measured older women on older formulas, and then the warning got stamped on every woman and every product (FDA/HHS, Nov 10, 2025).

The agency also makes an access argument with a striking number: in 2020, about 41 million U.S. women were ages 45–64, but only about 2 millionreceived a hormone-therapy prescription. The FDA's view is that fear of the old warning kept many women from a treatment that could have helped them (FDA press release, Feb 12, 2026).

It's fair to note this was a high-profile, politically framed announcement led by HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary. We're not here to score that. We're here to tell you what the labels say — and to add the expert voices the press conference didn't dwell on.

Does the FDA label change apply to compounded or “bioidentical” hormones?

• Compounded hormonesare custom-mixed by a compounding pharmacy. They don't carry FDA-approved labeling, and the FDA does not verify their safety, effectiveness, or quality before marketing. The boxed warning lived on FDA-approvedlabels, so the 2026 change simply doesn't touch compounded products.
• “Bioidentical”is a marketing word, not an FDA category. And here's the part the marketing often blurs: some FDA-approved products are bioidentical too. Prometrium, for example, is progesterone that the FDA label describes as chemically identicalto the progesterone your ovaries make. Estradiol products like Divigel are also “bioidentical” in that sense. So “bioidentical” does not automatically mean “compounded,” and it does not automatically mean “safer” or “better.”

If a provider tells you their compounded “bioidentical” cream is now FDA-cleared because of the 2026 news — that's not accurate, and it's a sign to ask sharper questions:

• Is what you'll prescribe an FDA-approved product, or a compounded one?
• Which pharmacy fills it?
• What monitoring and follow-up are included — not just the prescription?
• What happens if I have side effects or unexpected bleeding?

We're an independent comparison resource for HRT telehealth providers, so we'll put it plainly: the regulatory difference between FDA-approved and compounded changes what you can actually verify. Keep the two separate in your head. For a full breakdown, see our independent comparison of HRT telehealth providers.

Who should still be careful about HRT?

There's a real difference between a labeled contraindication(a condition where the label says don't use the product) and a reason to be cautious (something to talk through):

Source: FDA labels for the products listed above, Feb 2026; expert guidance via Breastcancer.org.

None of this is a reason to feel discouraged. It's a reason to get a real evaluation instead of self-prescribing off a headline. The 2026 change gives you permission to have the conversation— it doesn't replace it.

How do I check my own HRT label?

1. Find the exact product name on your prescription label or pill bottle.
2. Search it in Drugs@FDA or on DailyMed.
3. Open the current prescribing information (the most recent label).
4. Read these sections: Boxed Warning, Contraindications, Warnings and Precautions, and the Medication Guide.
5. Note your route: is it systemic (pill, patch, gel) or local (vaginal)?
6. Bring it — or a screenshot — to your clinician. That single step turns a confusing headline into a focused, two-way conversation.

If your pharmacy handout or an old web page still looks scarier than the current FDA label, that's normal — updates roll out unevenly. The current FDA prescribing information is the source that counts.

What this means for you — and what to do next

Where you go from here depends on where you're standing right now:

Bring this to your appointment

These are the questions that actually move an HRT decision forward after the 2026 change:

1. Is my situation better suited to full-body HRT or local vaginal estrogen?
2. Am I under 60 or within 10 years of menopause — and how does that change things for me?
3. Do I have any conditions that make HRT a bad idea?
4. Do I still have my uterus — and if I take systemic estrogen, what's the endometrial-protection plan?
5. Is what you're prescribing FDA-approved or compounded?
6. Which warnings still apply to my specific product and history?
7. How will we track whether it's helping, and what side effects should I report right away?
8. What are my non-hormonal options if HRT isn't a fit?

Frequently asked questions

All answers are based on the six updated FDA labels (February 2026) and official FDA/HHS press releases. For your personal situation, talk to a clinician.

When did the FDA remove the HRT black box warning?

The FDA announced it would remove the warnings on November 10, 2025, and approved the first updated labels on February 12, 2026. The two dates are why the news felt like it happened twice.

What warnings did the FDA remove from HRT?

Cardiovascular (heart) disease, breast cancer, and probable dementia were removed from the boxed warning — the most prominent box at the top of the label, where that boxed warning applied. On the systemic products, that information still appears lower in the label.

What HRT warning stayed?

For the estrogen-only products (Divigel, Cenestin, Enjuvia), the boxed warning for endometrial (uterine) cancer stayed in place for women with a uterus. The combination product, Bijuva, had its entire box removed because it already contains progesterone.

Does this mean HRT no longer carries breast cancer risk?

No. It means breast cancer was removed from the boxed warning. The updated labels still discuss breast-cancer risk and still list breast cancer as a condition where these products should not be used.

Is the dementia warning gone?

The probable-dementia warning was removed from both the boxed warning and the warnings section on the products we checked. The study it came from — the Women's Health Initiative Memory Study — is still described in the labels' clinical-studies section.

Does the FDA label change apply to compounded or "bioidentical" hormones?

No. It applies to FDA-approved products only. Compounded hormones are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality before marketing. Note that some FDA-approved products (like micronized progesterone and estradiol) are bioidentical too.

Which HRT products got updated labels first?

Six: Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva. The FDA says 29 companies submitted changes, so more will follow.

Does this apply to testosterone or TRT?

No. This is about menopausal estrogen and progesterone. Testosterone is regulated separately and is a Schedule III controlled substance that requires a prescription.

Should I stop or change my HRT because of this news?

No one should start, stop, or switch hormone therapy based on a headline. Use the change as a reason to review your current product and questions with a qualified clinician.

Do I still need a prescription for HRT?

Yes. Every FDA-approved HRT product requires a prescription and an evaluation by a licensed provider.

How we verified this